| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 10, 2013Company Offers Mapping System with IntellaMap Orion™ Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter...
-
May 10, 2013Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) followed in the...
-
May 6, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi? XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia...
-
Jan 16, 2013
The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Temperature...
-
Dec 17, 2012Company Begins Evaluation of its Next Generation Pacing Leads
The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial designed to establish the safety, performance...